Amendment to the Claims:

Cancel Claims 17, 18, 19, 21, 22, and 23.

Listing of Claims:

1. (original) A compound of structural formula I:



I

wherein:

each n is independently 0, 1, 2, or 3;

X is selected from S, S(O), $S(O)_2$, CH_2, CHF, and CF_2;

R^1 is hydrogen or -CN;

R^2 is selected from the group consisting of

hydrogen,

C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO_2H, C_{1-6} alkyloxycarbonyl, and

$(CH_2)_n$-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO_2H, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

R^3, R^4, R^5, and R^6 are each independently selected from the group consisting of

hydrogen,

halogen,

cyano,

hydroxy,

C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens,

C_{1-6} alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

$(CH_2)_n$-COOH,

$(CH_2)_n$-$COOC_{1-6}$ alkyl,

$(CH_2)_n$-$CONR^7R^8$,

$(CH_2)_n$-NR^7R^8,

$(CH_2)_n$-$NR^{10}SO_2R^9$,

$(CH_2)_n$-$NR^{10}CONR^7R^8$,

$(CH_2)_n$-$NR^{10}COR^{10}$,

$(CH_2)_n$-$NR^{10}CO_2R^9$,

$(CH_2)_n$-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO_2H, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

wherein any methylene (CH_2) carbon atom in R^3, R^4, R^5, and R^6 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C_{1-4} alkyl unsubstituted or substituted with one to five halogens;

R^7 and R^8 are each independently selected from the group consisting of

hydrogen,

$(CH_2)_n$-phenyl,

$(CH_2)_n$-C_{3-6} cycloalkyl, and

C_{1-10} alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; or

R^7 and R^8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy,

C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

R^9 is selected from the group consisting of $(CH_2)_n$-phenyl, $(CH_2)_n$-C_{3-6} cycloalkyl, and C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene (CH_2) carbon atom in R^9 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C_{1-4} alkyl unsubstituted or substituted with one to five halogens; and

each R^{10} is hydrogen or R^9.

2. (original) The compound of Claim 1 of structural formula Ia wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula Ia:



Ia

3. (original) The compound of Claim 1 wherein X is S, S(O), or $S(O)_2$.

4. (original) The compound of Claim 3 wherein R^1 is hydrogen.

5. (original) The compound of Claim 2 wherein X is S, S(O), or $S(O)_2$.

6. (original) The compound of Claim 1 wherein X is CH_2, CHF, or CF_2.

7. (original) The compound of Claim 6 wherein R^1 is hydrogen.

8. (original) The compound of Claim 2 wherein X is CH_2, CHF, or CF_2.

9. (original) The compound of Claim 1 wherein R^2 is hydrogen, methyl, or phenyl.

10. (original) The compound of Claim 9 wherein R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, trifluoromethyl, trifluoromethoxy, carboxy, and $COOC_{1-4}$ alkyl.

11. (original) The compound of Claim 10 wherein R^4 and R^6 are hydrogen.

12. (original) The compound of Claim 11 of structural formula II selected from the group consisting of:



(II)

X	R^2	R^3	R^5
S	H	H	Cl
CH_2	H	H	Cl
CH_2	H	H	OCF_3
CH_2	H	H	CF_3
CH_2	H	CO_2H	H
CH_2	H	CO_2Et	H
CH_2	H	H	CO_2H

CH_2	H	H	CO_2Et
CH_2	H	CF_3	H
CF_2	H	CONH*n*-Dec	H
CH_2	Me	H	H
CH_2	Ph	H	H

13. (original) A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

14. (original) A method for treating diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

15. (original) A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

16. (original) A method for treating hyperglycemia in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

17-19. (cancelled)

20. (original) The pharmaceutical composition of Claim 13 further comprising one or more additional active ingredients selected from the group consisting of:

(a) a second dipeptidyl peptidase IV inhibitor;

(b) an insulin sensitizer selected from the group consisting of a PPARγ agonist, a PPARα/γ dual agonist, a PPARα agonist, a biguanide, and a protein tyrosine phosphatase-1B inhibitor;

(c) an insulin or insulin mimetic;

(d) a sulfonylurea or other insulin secretagogue;

(e) an α-glucosidase inhibitor;

(f) a glucagon receptor antagonist;

(g) GLP-1, a GLP-1 mimetic, or a GLP-1 receptor agonist;

(h) GIP, a GIP mimetic, or a GIP receptor agonist;

(i) PACAP, a PACAP mimetic, or a PACAP receptor agonist;

(j) a cholesterol lowering agent such as (i) HMG-CoA reductase inhibitor, (ii) sequestrant, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonist, (v) PPARα/γ dual agonist, (vi) inhibitor of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitor, and (viii) anti-oxidant;

(k) a PPARδ agonist;

(l) an antiobesity compound;

(m) an ileal bile acid transporter inhibitor;

(n) an anti-inflammatory agent; and

(o) an antihypertensive agent.

21-23 (cancelled)